Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP
Condition: Metastatic Breast Cancer Intervention: Drug: PARP inhibitor 2X-121 Sponsors: Oncology Venture; Smerud Medical Research International AS; Danish Breast Cancer Cooperative Group Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials